Wart Remover

Description

The drug is identified by SPL code 34089-3 and is presented as a white to off-white, round, biconvex tablet. The tablet is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. Inactive ingredients consist of lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts. Common warts are characterized by a rough, "cauliflower-like" surface and are easily recognizable. Plantar warts are specifically located on the soles of the feet, presenting as tender to touch and exhibiting an interrupted footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely.

A sufficient amount of the medication should be applied using a cotton swab to ensure complete coverage of each wart. It is important to allow the application to dry fully.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

• Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

• The product should not be applied to moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, as these areas may be sensitive or require specialized treatment.

• Patients with diabetes or poor blood circulation should not use this product, as these conditions may increase the risk of adverse effects.

Additionally, avoid contact with the eyes. In the event of contact, flush the eyes with water for 15 minutes.

Warnings and Precautions

For external use only. In the event of accidental ingestion, it is imperative to seek medical assistance immediately or contact the Poison Control Center at 1-800-222-1222.

This product should not be applied to irritated skin or any areas that are infected or exhibit redness. It is contraindicated for use on moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes. Additionally, individuals with diabetes or compromised blood circulation should avoid using this product.

If discomfort persists after application, the user should discontinue use and consult a healthcare professional for further evaluation and guidance.

Side Effects

For external use only. Patients should be advised to stop use and consult a doctor if discomfort persists.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Wart Remover (salicylic acid 17%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should use this product for external application only. Care should be taken to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes. If discomfort persists, it is advised to stop use and consult a healthcare professional.

Prior to application, the affected area should be washed and may be soaked in warm water for 5 minutes. The area must be dried thoroughly before treatment. A sufficient amount of the product should be applied using a cotton swab to cover each wart, allowing it to dry. This procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

Geriatric Use

There is no specific information regarding the use of WART REMOVER (salicylic acid 17% liquid) in geriatric patients. The prescribing information does not indicate any dosage adjustments, safety concerns, or special precautions that are specifically applicable to elderly patients.

Healthcare providers should exercise clinical judgment when considering the use of this product in geriatric patients, as individual patient factors may influence treatment outcomes. Monitoring for efficacy and potential adverse effects is advisable, given the lack of targeted data for this population.

Pregnancy

Safety during pregnancy has not been established for this medication. Use is not recommended during pregnancy due to potential risks to the fetus. Healthcare professionals should consider alternative treatments for pregnant patients to avoid any adverse fetal outcomes. Women of childbearing potential should be counseled on the potential risks associated with the use of this medication during pregnancy.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. The effects on breastfed infants have not been established, and further research may be necessary to determine any implications for breastfeeding.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, it is important for healthcare professionals to remain vigilant and consider general principles of management in cases of suspected overdose with any medication.

Healthcare providers should monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention is warranted. Recommended actions include contacting a poison control center or seeking emergency medical assistance. Supportive care should be initiated as necessary, which may involve maintaining airway patency, providing supplemental oxygen, and administering intravenous fluids to manage hemodynamic stability.

It is essential for healthcare professionals to refer to specific treatment guidelines and protocols relevant to the substance involved in the overdose for tailored management strategies.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center at 1-800-222-1222 if the product is swallowed.

Patients should be informed to avoid contact with their eyes. In the event that the product comes into contact with the eyes, they should flush the eyes with water for at least 15 minutes. It is important to emphasize that the product is non-edible and should be stored with the cap tightly closed at room temperature, away from heat sources.

Additionally, healthcare providers should instruct patients to discontinue use and consult a doctor if any discomfort persists.

Storage and Handling

The product is supplied in a tightly capped container. It should be stored at room temperature, ensuring it is kept away from heat sources to maintain its integrity and efficacy.

Additional Clinical Information

The medication is administered topically, with a recommended application method involving the use of a cotton swab to apply a sufficient amount to cover each wart. The application should be allowed to dry, and this procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)